


PHARMACEUTICAL 2019

G1 Therapeutics Inc. Rank 80 of 371







PHARMACEUTICAL 2019



G1 Therapeutics Inc. Rank 80 of 371



The relative strengths and weaknesses of G1 Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of G1 Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 369% points. The greatest weakness of G1 Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 54% points.

The company's Economic Capital Ratio, given in the ranking table, is 25%, being 357% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	370,133
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,362
Liabilities, Non-Current	88
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	3,998
Property and Equipment	1,137
Research and Development	70,683
Revenues	0
Selling, General and Administrative Expense	18,603

Output Variable	Value in 1000 USD
Assets	371,270
Liabilities	12,450
Expenses	89,286
Stockholders Equity	358,820
Net Income	-85,288
Comprehensive Net Income	-85,288
Economic Capital Ratio	25%